

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/58, C12P 19/34, C07H 21/04		A1	(11) International Publication Number: WO 00/08206 (43) International Publication Date: 17 February 2000 (17.02.00)
(21) International Application Number: PCT/US99/16247 (22) International Filing Date: 19 July 1999 (19.07.99) (30) Priority Data: 60/095,233 4 August 1998 (04.08.98) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/095,233 (CIP) Filed on 4 August 1998 (04.08.98) (71) Applicant (for all designated States except US): DIADEXUS LLC [US/US]; 3303 Octavius Drive, Santa Clara, CA 95054 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): YANG, Fei [CN/CN]; Apartment L-316, 655 South Fair Oaks Avenue, Sunnyvale, CA 94086 (US). SUN, Yongming [CN/CN]; Apartment 260, 869 Winchester Boulevard, San Jose, CA 95128 (US). RECIPON, Herve [FR/FR]; 85 Fortuna Avenue, San Francisco, CA 94115 (US). MACINA, Roberto, A. [AR/AR]; 4118 Crescendo Avenue, San Jose, CA 95136 (US).			(74) Agents: LICATA, Jane, Massey et al.; Law Offices of Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053 (US). (81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING, IMAGING AND TREATING LUNG CANCER (57) Abstract <p>The present invention provides new methods for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating lung cancer.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

**A NOVEL METHOD OF DIAGNOSING,
MONITORING, STAGING, IMAGING AND TREATING LUNG CANCER**

FIELD OF THE INVENTION

This invention relates, in part, to newly developed
5 assays for detecting, diagnosing, monitoring, staging,
prognosticating, imaging and treating cancers, particularly
lung cancer.

BACKGROUND OF THE INVENTION

10 Lung cancer is the second most prevalent type of cancer
for both men and women in the United States and is the most
common cause of cancer death in both sexes. Lung cancer can
result from a primary tumor originating in the lung or a
secondary tumor which has spread from another organ such as
15 the bowel or breast. Primary lung cancer is divided into
three main types; small cell lung cancer; non-small cell lung
cancer; and mesothelioma. Small cell lung cancer is also
called "Oat Cell" lung cancer because the cancer cells are a
distinctive oat shape. There are three types of non-small cell
20 lung cancer. These are grouped together because they behave
in a similar way and respond to treatment differently to small
cell lung cancer. The three types are squamous cell
carcinoma, adenocarcinoma, and large cell carcinoma. Squamous
cell cancer is the most common type of lung cancer. It
25 develops from the cells that line the airways. Adenocarcinoma
also develops from the cells that line the airways. However,
adenocarcinoma develops from a particular type of cell that
produces mucus (phlegm). Large cell lung cancer has been thus
named because the cells look large and rounded when they are
30 viewed under a microscope. Mesothelioma is a rare type of
cancer which affects the covering of the lung called the
pleura. Mesothelioma is often caused by exposure to asbestos.

- 2 -

Secondary lung cancer is cancer that has started somewhere else in the body (for example, the breast or bowel) and spread to the lungs. Choice of treatment for secondary lung cancer depends on where the cancer started. In other
5 words, cancer that has spread from the breast should respond to breast cancer treatments and cancer that has spread from the bowel should respond to bowel cancer treatments.

The stage of a cancer indicates how far a cancer has spread. Staging is important because treatment is often
10 decided according to the stage of a cancer. The staging is different for non-small cell and for small cell cancers of the lung.

Non-small cell cancer can be divided into four stages. Stage I is very localized cancer with no cancer in the lymph
15 nodes. Stage II cancer has spread to the lymph nodes at the top of the affected lung. Stage III cancer has spread near to where the cancer started. This can be to the chest wall, the covering of the lung (pleura), the middle of the chest (mediastinum) or other lymph nodes. Stage IV cancer has
20 spread to another part of the body.

Since small cell lung cancer can spread quite early in development of the disease, small cell lung cancers are divided into only two groups. These are: limited disease, that is cancer that can only be seen in one lung and in nearby
25 lymph nodes; and extensive disease, that is cancer that has spread outside the lung to the chest or to other parts of the body. Further, even if spreading is not apparent on the scans, it is likely that some cancer cells will have broken away and traveled through the bloodstream or lymph system.
30 To be safe, it is therefore preferred to treat small cell lung cancers as if they have spread, whether or not secondary cancer is visible. Because surgery is not typically used to treat small cell cancer, except in very early cases, the staging is not as critical as it is with some other types of
35 cancer. Chemotherapy with or without radiotherapy is often

- 3 -

employed. The scans and tests done at first will be used later to see how well a patient is responding to treatment.

WO 98/56951 (published December 17, 1998) discloses a set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as LS170. These sequences are suggested to be useful in detecting, diagnosing, staging, monitoring, prognosticating, *in vivo* imaging, preventing or treating, and determining the predisposition of an individual to disease and conditions of the lung, such as lung cancer. The LS170-specific polynucleotide is taught to have at least 50% identity with a polynucleotide selected from the group consisting of SEQ ID NO:1-9 as disclosed in WO 98/56951. SEQ ID NO:1 taught in WO 98/56951 overlaps with an LSG, SEQ ID NO: 4, used in the instant invention.

In the present invention methods are provided for detecting, diagnosing, monitoring, staging, prognosticating, *in vivo* imaging and treating lung cancer via five (5) Lung Specific Genes (LSG). The five LSGs refer, among other things, to native proteins expressed by the genes comprising the polynucleotide sequences of any of SEQ ID NO: 1, 2, 3, 4, or 5. In the alternative, what is meant by the five LSGs as used herein, means the native mRNAs encoded by the genes comprising any of the polynucleotide sequences of SEQ ID NO: 1, 2, 3, 4, or 5 or it can refer to the actual genes comprising any of the polynucleotide sequences of SEQ ID NO: 1, 2, 3, 4, or 5.

Procedures used for detecting, diagnosing, monitoring, staging, and prognosticating lung cancer are of critical importance to the outcome of the patient. For example, patients diagnosed with early lung cancer generally have a much greater five-year survival rate as compared to the survival rate for patients diagnosed with distant metastasized lung cancer. New diagnostic methods which are more sensitive and specific for detecting early lung cancer are clearly needed.

- 4 -

Lung cancer patients are closely monitored following initial therapy and during adjuvant therapy to determine response to therapy and to detect persistent or recurrent disease of metastasis. There is clearly a need for a lung
5 cancer marker which is more sensitive and specific in detecting lung cancer, its recurrence and progression.

Another important step in managing lung cancer is to determine the stage of the patient's disease. Stage determination has potential prognostic value and provides
10 criteria for designing optimal therapy. Generally, pathological staging of lung cancer is preferable over clinical staging because the former gives a more accurate prognosis. However, clinical staging would be preferred were it at least as accurate as pathological staging because it
15 does not depend on an invasive procedure to obtain tissue for pathological evaluation. Staging of lung cancer would be improved by detecting new markers in cells, tissues, or bodily fluids which could differentiate between different stages of invasion.

20 Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of
25 the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

30 SUMMARY OF THE INVENTION

Toward these ends, and others, it is an object of the present invention to provide a method for diagnosing the presence of lung cancer by analyzing for changes in levels of LSG in cells, tissues or bodily fluids compared with levels

- 5 -

of LSG in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in levels of LSG in the patient versus normal human control is associated with lung cancer.

5 Further provided is a method of diagnosing metastatic lung cancer in a patient having such cancer which is not known to have metastasized by identifying a human patient suspected of having lung cancer that has metastasized; analyzing a sample of cells, tissues, or bodily fluid from such patient
10 for LSG; comparing the LSG levels in such cells, tissues, or bodily fluid with levels of LSG in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in LSG levels in the patient versus the normal human control is associated with a cancer which has
15 metastasized.

Also provided by the invention is a method of staging lung cancer in a human which has such cancer by identifying a human patient having such cancer; analyzing a sample of cells, tissues, or bodily fluid from such patient for LSG;
20 comparing LSG levels in such cells, tissues, or bodily fluid with levels of LSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in LSG levels in the patient versus the normal human control is associated with a cancer which is progressing
25 and a decrease in the levels of LSG is associated with a cancer which is regressing or in remission.

Further provided is a method of monitoring lung cancer in a human having such cancer for the onset of metastasis. The method comprises identifying a human patient having such
30 cancer that is not known to have metastasized; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for LSG; comparing the LSG levels in such cells, tissue, or bodily fluid with levels of LSG in preferably the same cells, tissues, or bodily fluid type of a normal human
35 control sample, wherein an increase in LSG levels in the

- 6 -

patient versus the normal human control is associated with a cancer which has metastasized.

Further provided is a method of monitoring the change in stage of lung cancer in a human having such cancer by looking
5 at levels of LSG in a human having such cancer. The method comprises identifying a human patient having such cancer; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for LSG; comparing the LSG levels in such cells, tissue, or bodily fluid with levels of LSG in
10 preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in LSG levels in the patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of LSG is associated with a cancer which is
15 regressing or in remission.

Further provided are antibodies against the LSGs or fragments of such antibodies which can be used to detect or image localization of the LSGs in a patient for the purpose of detecting or diagnosing a disease or condition. Such
20 antibodies can be polyclonal or monoclonal, or prepared by molecular biology techniques. The term "antibody", as used herein and throughout the instant specification is also meant to include aptamers and single-stranded oligonucleotides such as those derived from an *in vitro* evolution protocol referred
25 to as SELEX and well known to those skilled in the art. Antibodies can be labeled with a variety of detectable labels including, but not limited to, radioisotopes and paramagnetic metals. These antibodies or fragments thereof can also be used as therapeutic agents in the treatment of diseases
30 characterized by expression of a LSG. In therapeutic applications, the antibody can be used without or with derivatization to a cytotoxic agent such as a radioisotope, enzyme, toxin, drug or a prodrug.

Other objects, features, advantages and aspects of the
35 present invention will become apparent to those of skill in

- 7 -

the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

DESCRIPTION OF THE INVENTION

10 The present invention relates to diagnostic assays and methods, both quantitative and qualitative for detecting, diagnosing, monitoring, staging, prognosticating, *in vivo* imaging and treating cancers by comparing levels of LSG with those of LSG in a normal human control. What is meant by
15 levels of LSG as used herein, means levels of the native protein expressed by the gene comprising the polynucleotide sequence of any of SEQ ID NO: 1, 2, 3, 4, or 5. In the alternative, what is meant by levels of LSG as used herein, means levels of the native mRNA encoded by the gene comprising
20 any of the polynucleotide sequences of SEQ ID NO: 1, 2, 3, 4, or 5 or levels of the gene comprising any of the polynucleotide sequence of SEQ ID NO: 1, 2, 3, 4, or 5. Such levels are preferably measured in at least one of, cells, tissues and/or bodily fluids, including determination of
25 normal and abnormal levels. Thus, for instance, a diagnostic assay in accordance with the invention for diagnosing over-expression of LSG protein compared to normal control bodily fluids, cells, or tissue samples may be used to diagnose the presence of cancers, including lung cancer. Any of the five
30 LSGs may be measured alone in the methods of the invention, or all together or any combination of the five.

All the methods of the present invention may optionally include measuring the levels of other cancer markers as well as LSG. Other cancer markers, in addition to LSG, useful in

- 8 -

the present invention will depend on the cancer being tested and are known to those of skill in the art.

Diagnostic Assays

The present invention provides methods for diagnosing the presence of lung cancer by analyzing for changes in levels of LSG in cells, tissues or bodily fluids compared with levels of LSG in cells, tissues or bodily fluids of preferably the same type from a normal human control, wherein an increase in levels of LSG in the patient versus the normal human control is associated with the presence of lung cancer.

Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the patient being tested has cancer is one in which cells, tissues, or bodily fluid levels of the cancer marker, such as LSG, are at least two times higher, and most preferable are at least five times higher, than in preferably the same cells, tissues, or bodily fluid of a normal human control.

The present invention also provides a method of diagnosing metastatic lung cancer in a patient having lung cancer which has not yet metastasized for the onset of metastasis. In the method of the present invention, a human cancer patient suspected of having lung cancer which may have metastasized (but which was not previously known to have metastasized) is identified. This is accomplished by a variety of means known to those of skill in the art. For example, in the case of lung cancer, patients are typically diagnosed with lung cancer following traditional detection methods.

In the present invention, determining the presence of LSG level in cells, tissues, or bodily fluid, is particularly useful for discriminating between lung cancer which has not metastasized and lung cancer which has metastasized. Existing techniques have difficulty discriminating between lung cancer which has metastasized and lung cancer which has not

- 9 -

metastasized and proper treatment selection is often dependent upon such knowledge.

In the present invention, the cancer marker level measured in such cells, tissues, or bodily fluid is LSG, and
5 is compared with levels of LSG in preferably the same cells, tissue, or bodily fluid type of a normal human control. That is, if the cancer marker being observed is just LSG in serum, this level is preferably compared with the level of LSG in serum of a normal human patient. An increase in the LSG in
10 the patient versus the normal human control is associated with lung cancer which has metastasized.

Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the cancer in the patient being tested or monitored has
15 metastasized is one in which cells, tissues, or bodily fluid levels of the cancer marker, such as LSG, are at least two times higher, and more preferably are at least five times higher, than in preferably the same cells, tissues, or bodily fluid of a normal patient.

20 Normal human control as used herein includes a human patient without cancer and/or non cancerous samples from the patient; in the methods for diagnosing metastasis or monitoring for metastasis, normal human control preferably includes samples from a human patient that is determined by
25 reliable methods to have lung cancer which has not metastasized such as samples from the same patient prior to metastasis.

Staging

The invention also provides a method of staging lung
30 cancer in a human patient.

The method comprises identifying a human patient having such cancer and analyzing a sample of cells, tissues, or bodily fluid from such patient for LSG. The measured LSG levels are then compared to levels of LSG in preferably the

- 10 -

same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in LSG levels in the patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of LSG is associated with a cancer which is regressing or in remission.

Monitoring

Further provided is a method of monitoring lung cancer in a human having such cancer for the onset of metastasis. The method comprises identifying a human patient having such cancer that is not known to have metastasized; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for LSG; comparing the LSG levels in such cells, tissue, or bodily fluid with levels of LSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in LSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.

Further provided by this inventions is a method of monitoring the change in stage of lung cancer in a human having such cancer. The method comprises identifying a human patient having such cancer; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for LSG; comparing the LSG levels in such cells, tissue, or bodily fluid with levels of LSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in LSG levels in the patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease in the levels of LSG is associated with a cancer which is regressing in stage or in remission.

Monitoring such patient for onset of metastasis is periodic and preferably done on a quarterly basis. However,

- 11 -

this may be more or less frequent depending on the cancer, the particular patient, and the stage of the cancer.

Assay Techniques

Assay techniques that can be used to determine levels of
5 gene expression, such as LSG of the present invention, in a
sample derived from a host are well-known to those of skill
in the art. Such assay methods include radioimmunoassays,
reverse transcriptase PCR (RT-PCR) assays,
immunohistochemistry assays, *in situ* hybridization assays,
10 competitive-binding assays, Western Blot analyses, ELISA
assays and proteomic approaches. Among these, ELISAs are
frequently preferred to diagnose a gene's expressed protein
in biological fluids.

An ELISA assay initially comprises preparing an antibody,
15 if not readily available from a commercial source, specific
to LSG, preferably a monoclonal antibody. In addition a
reporter antibody generally is prepared which binds
specifically to LSG. The reporter antibody is attached to a
detectable reagent such as radioactive, fluorescent or
20 enzymatic reagent, for example horseradish peroxidase enzyme
or alkaline phosphatase.

To carry out the ELISA, antibody specific to LSG is
incubated on a solid support, e.g., a polystyrene dish, that
binds the antibody. Any free protein binding sites on the
25 dish are then covered by incubating with a non-specific
protein such as bovine serum albumin. Next, the sample to be
analyzed is incubated in the dish, during which time LSG
binds to the specific antibody attached to the polystyrene
dish. Unbound sample is washed out with buffer. A reporter
30 antibody specifically directed to LSG and linked to
horseradish peroxidase is placed in the dish resulting in
binding of the reporter antibody to any monoclonal antibody
bound to LSG. Unattached reporter antibody is then washed
out. Reagents for peroxidase activity, including a

- 12 -

colorimetric substrate are then added to the dish. Immobilized peroxidase, linked to LSG antibodies, produces a colored reaction product. The amount of color developed in a given time period is proportional to the amount of LSG protein present in the sample. Quantitative results typically are obtained by reference to a standard curve.

A competition assay may be employed wherein antibodies specific to LSG attached to a solid support and labeled LSG and a sample derived from the host are passed over the solid support and the amount of label detected attached to the solid support can be correlated to a quantity of LSG in the sample.

Nucleic acid methods may be used to detect LSG mRNA as a marker for lung cancer. Polymerase chain reaction (PCR) and other nucleic acid methods, such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASABA), can be used to detect malignant cells for diagnosis and monitoring of various malignancies. For example, reverse-transcriptase PCR (RT-PCR) is a powerful technique which can be used to detect the presence of a specific mRNA population in a complex mixture of thousands of other mRNA species. In RT-PCR, an mRNA species is first reverse transcribed to complementary DNA (cDNA) with use of the enzyme reverse transcriptase; the cDNA is then amplified as in a standard PCR reaction. RT-PCR can thus reveal by amplification the presence of a single species of mRNA. Accordingly, if the mRNA is highly specific for the cell that produces it, RT-PCR can be used to identify the presence of a specific type of cell.

Hybridization to clones or oligonucleotides arrayed on a solid support (i.e., gridding) can be used to both detect the expression of and quantitate the level of expression of that gene. In this approach, a cDNA encoding the LSG gene is fixed to a substrate. The substrate may be of any suitable type including but not limited to glass, nitrocellulose, nylon or plastic. At least a portion of the DNA encoding the LSG

- 13 -

gene is attached to the substrate and then incubated with the analyte, which may be RNA or a complementary DNA (cDNA) copy of the RNA, isolated from the tissue of interest. Hybridization between the substrate bound DNA and the analyte
5 can be detected and quantitated by several means including but not limited to radioactive labeling or fluorescence labeling of the analyte or a secondary molecule designed to detect the hybrid. Quantitation of the level of gene expression can be done by comparison of the intensity of the signal from the
10 analyte compared with that determined from known standards. The standards can be obtained by *in vitro* transcription of the target gene, quantitating the yield, and then using that material to generate a standard curve.

Of the proteomic approaches, 2D electrophoresis is a
15 technique well known to those in the art. Isolation of individual proteins from a sample such as serum is accomplished using sequential separation of proteins by different characteristics usually on polyacrylamide gels. First, proteins are separated by size using an electric
20 current. The current acts uniformly on all proteins, so smaller proteins move farther on the gel than larger proteins. The second dimension applies a current perpendicular to the first and separates proteins not on the basis of size but on the specific electric charge carried by each protein. Since
25 no two proteins with different sequences are identical on the basis of both size and charge, the result of a 2D separation is a square gel in which each protein occupies a unique spot. Analysis of the spots with chemical or antibody probes, or subsequent protein microsequencing can reveal the relative
30 abundance of a given protein and the identity of the proteins in the sample.

The above tests can be carried out on samples derived from a variety of patients' cells, bodily fluids and/or tissue extracts (homogenates or solubilized tissue) such as from
35 tissue biopsy and autopsy material. Bodily fluids useful in

- 14 -

the present invention include blood, urine, saliva, or any other bodily secretion or derivative thereof. Blood can include whole blood, plasma, serum, or any derivative of blood.

5 *In Vivo Antibody Use*

Antibodies against LSG can also be used *in vivo* in patients with disease of the lung. Specifically, antibodies against an LSG can be injected into a patient suspected of having a disease of the lung for diagnostic and/or therapeutic
10 purposes. The use of antibodies for *in vivo* diagnosis is well known in the art. For example, antibody-chelators labeled with Indium-111 have been described for use in the radioimmunoscentographic imaging of carcinoembryonic antigen expressing tumors (Sumerdon et al. Nucl. Med. Biol. 1990
15 17:247-254). In particular, these antibody-chelators have been used in detecting tumors in patients suspected of having recurrent colorectal cancer (Griffin et al. J. Clin. Onc. 1991 9:631-640). Antibodies with paramagnetic ions as labels for use in magnetic resonance imaging have also been described
20 (Laufer, R.B. Magnetic Resonance in Medicine 1991 22:339-342). Antibodies directed against LSGs can be used in a similar manner. Labeled antibodies against an LSG can be injected into patients suspected of having a disease of the lung such as lung cancer for the purpose of diagnosing or
25 staging of the disease status of the patient. The label used will be selected in accordance with the imaging modality to be used. For example, radioactive labels such as Indium-111, Technetium-99m or Iodine-131 can be used for planar scans or single photon emission computed tomography (SPECT). Positron
30 emitting labels such as Fluorine-19 can be used in positron emission tomography. Paramagnetic ions such as Gadolinium (III) or Manganese (II) can be used in magnetic resonance imaging (MRI). Localization of the label within the lung or external to the lung permits determination of the spread of the
35 disease. The amount of label within the lung also allows

- 15 -

determination of the presence or absence of cancer in the lung.

For patients diagnosed with lung cancer, injection of an antibody against an LSG can also have a therapeutic benefit.

5 The antibody may exert its therapeutic effect alone. Alternatively, the antibody is conjugated to a cytotoxic agent such as a drug, toxin or radionuclide to enhance its therapeutic effect. Drug monoclonal antibodies have been described in the art for example by Garnett and Baldwin,

10 *Cancer Research* 1986 46:2407-2412. The use of toxins conjugated to monoclonal antibodies for the therapy of various cancers has also been described by Pastan et al. *Cell* 1986 47:641-648). Yttrium-90 labeled monoclonal antibodies have been described for maximization of dose delivered to the tumor

15 while limiting toxicity to normal tissues (Goodwin and Meares *Cancer Supplement* 1997 80:2675-2680). Other cytotoxic radionuclides including, but not limited to Copper-67, Iodine-131 and Rhenium-186 can also be used for labeling of antibodies against LSGs.

20 Antibodies which can be used in these *in vivo* methods include both polyclonal and monoclonal antibodies and antibodies prepared via molecular biology techniques. Antibody fragments can also be used.

EXAMPLES

25 The present invention is further described by the following examples. The examples are provided solely to illustrate the invention by reference to specific embodiments. These exemplifications, while illustrating certain specific aspects of the invention, do not portray the limitations or

30 circumscribe the scope of the disclosed invention.

Example 1

Searches were carried out and LSGs identified using the following Search Tools as part of the LIFESEQ database available from Incyte Pharmaceuticals, Palo Alto, CA:

- 5 Library Comparison (compares one library to one other library) allows the identification of clones expressed in tumor and absent or expressed at a lower level in normal tissue.

10 Subsetting is similar to library comparison but allows the identification of clones expressed in a pool of libraries and absent or expressed at a lower level in a second pool of libraries.

15 Transcript Imaging lists all of the clones in a single library or a pool of libraries based on abundance. Individual clones can then be examined using Electronic Northern to determine the tissue sources of their component ESTs.

20 Protein Function: Incyte has identified subsets of ESTs with a potential protein function based on homologies to known proteins. Some examples in this database include Transcription Factors and Proteases. Some leads were identified by searching in this database for clones whose component ESTs showed disease specificity.

25 Electronic subtractions, transcript imaging and protein function searches were used to identify clones, whose component ESTs were exclusively or more frequently found in libraries from specific tumors. Individual candidate clones were examined in detail by checking where each EST originated.

- 17 -

Table 1: LSGs

SEQ ID #	Clone ID	Gene ID	Method
1	2589190	6361	Transcript Imaging
2	1237018	6997	Transcript Imaging
5 3	1510111	5658	Transcript Imaging
4	1355520	236760	Transcript Imaging
5	3117390	7387	Transcript Imaging

The following example was carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. Routine molecular biology techniques of the following example can be carried out as described in standard laboratory manuals, such as Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).

Example 2: Relative Quantitation of Gene Expression.

Real-Time quantitative PCR with fluorescent Taqman probes is a quantitation detection system utilizing the 5'-3' nuclease activity of Taq DNA polymerase. The method uses an internal fluorescent oligonucleotide probe (Taqman) labeled with a 5' reporter dye and a downstream, 3' quencher dye. During PCR, the 5'-3' nuclease activity of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected by the laser detector of the Model 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA).

Amplification of an endogenous control is used to standardize the amount of sample RNA added to the reaction and normalize for Reverse Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or 18S ribosomal RNA (rRNA) was used as this endogenous

- 18 -

control. To calculate relative quantitation between all the samples studied, the target RNA levels for one sample were used as the basis for comparative results (calibrator). Quantitation relative to the "calibrator" can be obtained
5 using the standard curve method or the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence Detection System).

The tissue distribution and the level of the target gene were evaluated for every example in normal and cancer tissue. Total RNA was extracted from these tissues and corresponding
10 matched adjacent tissues. Subsequently, first strand cDNA was prepared with reverse transcriptase and the polymerase chain reaction was done using primers and Taqman probe specific to each target gene. The results were analyzed using the ABI PRISM 7700 Sequence Detector. The absolute numbers are
15 relative levels of expression of the target gene in a particular tissue compared to the calibrator tissue.

Comparative Examples

Similar mRNA expression analysis for genes coding for the diagnostic markers PSA (Prostate Specific Antigen) and PLA2
20 (Phospholipase A2) was performed for comparison. PSA is the only cancer screening marker available in clinical laboratories. When the panel of normal pooled tissues was analyzed, PSA was expressed at very high levels in prostate, with a very low expression in breast and testis. After
25 analysis of more than 55 matching samples from 14 different tissues, the data corroborated the tissue specificity seen with normal tissue samples. PSA expression was compared in cancer and normal adjacent tissue for 12 matching samples of prostate tissue. The relative levels of PSA were higher in
30 10 cancer samples (83%). Clinical data recently obtained support the utilization of PLA2 as a staging marker for late stages of prostate cancer. mRNA expression data showed overexpression of the mRNA in 8 out of the 12 prostate matching samples analyzed (66%). The tissue specificity for
35 PLA2 was not as good as the one described for PSA. In

- 19 -

addition to prostate, small intestine, liver, and pancreas also showed high levels of mRNA expression for PLA2.

Measurement of SEQ ID NO:5; Clone ID3117390; Gene ID7387 (Lng109)

5 The absolute numbers shown in Table 2 are relative levels of expression of Lng109 (SEQ ID NO:5) in 12 normal different tissues. All the values are compared to normal small intestine (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular
10 tissue from different individuals.

Table 2: Relative levels of Lng109 Expression in Pooled Samples

	Tissue	NORMAL
15	Brain	26.6
	Heart	0.004
	Kidney	0.016
	Liver	0
	Lung	46.6
	Mammary Gland	0.2
20	Muscle	0.1
	Prostate	0.4
	Small	1
	Testis	12.1
	Thymus	0.2
25	Uterus	0.2

The relative levels of expression in Table 2 show that Lng109 (SEQ ID NO:5) mRNA expression is higher (46.6) in lung compared with all the other normal tissues analyzed. Testis, with a relative expression level of 12.1, and brain (26.6) are
30 the only other tissues expressing considerable mRNA for Lng109. These results establish that Lng109 mRNA expression is highly specific for lung.

The absolute numbers in Table 2 were obtained analyzing pools of samples of a particular tissue from different
35 individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 3.

- 20 -

The absolute numbers depicted in Table 3 are relative levels of expression of Lng109 (SEQ ID NO:5) in 57 pairs of matching samples. All the values are compared to normal small intestine (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.

Table 3: Relative levels of Lng109 Expression in Individual Samples

10	Sample ID	Cancer type	Tissue	Cancer	Matching Normal
	LNG AC82	Adenocarcinoma	Lung 1	16.6	0.9
	LNG 60XL	Adenocarcinoma	Lung 2	20.4	45.3
	LNG AC66	Adenocarcinoma	Lung 3	12.4	7.5
15	LNG AC69	Adenocarcinoma	Lung 4	177.9	4.2
	LNG AC88	Adenocarcinoma	Lung 5	89	33.7
	LNG AC11	Adenocarcinoma	Lung 6	20.3	88.3
	LNG AC39	Adenocarcinoma	Lung 7	103.3	1.8
	LNG AC90	Adenocarcinoma	Lung 8	342.5	0.9
20	LNG AC32	Adenocarcinoma	Lung 9	152.7	0
	LNG SQ9X	Squamous cell carcinoma	Lung 10	14.2	0.7
	LNG SQ45	Squamous cell carcinoma	Lung 11	179.8	15.9
	LNG SQ56	Squamous cell carcinoma	Lung 12	55.5	59.3
	LNG SQ32	Squamous cell carcinoma	Lung 13	21.3	6.4
25	LNG SQ80	Squamous cell carcinoma	Lung 14	83	36
	LNG SQ16	Squamous cell carcinoma	Lung 15	27.2	4.8
	LNG SQ79	Squamous cell carcinoma	Lung 16	11.2	18

- 21 -

5	LNG C20X	Squamous cell carcinoma	Lung 17	0.2	0.63
	LNG 47XQ	Squamous cell carcinoma	Lung 18	188.1	0
	LNG SQ44	Squamous cell carcinoma	Lung 19	6.3	0.2
	LNG BR94	Squamous cell carcinoma	Lung 20	12	0
	LNG 90X	Squamous cell carcinoma	Lung 21	7.6	3.6
10	LNG LC71	Large cell carcinoma	Lung 22	69.1	168.3
	LNG LC109	Large cell carcinoma	Lung 23	11.8	250.7
	LNG 75XC	Metastatic from bone cancer	Lung 24	1.5	1.8
	LNG MT67	Metastatic from renal cancer	Lung 25	3.1	2.7
	LNG MT71	Metastatic from melanoma	Lung 26	9.9	21.9
15	BLD 32XK		Bladder 1	0.1	0
	BLD 46XK		Bladder 2	0.3	0
	CLN AS67		Colon 1	0.2	0.1
	CLN C9XR		Colon 2	0.02	0
	CVX KS52		Cervix 1	0.1	0
20	CVX NK23		Cervix 2	0.1	0
	END 28XA		Endometrium 1	2.2	0.1
	ENDO 12XA		Endometrium 2	0	0
	ENDO 68X		Endometrium 3	1.33	2.6
	ENDO 8XA		Endometrium 4	0	0
25	KID 106XD		Kidney 1	0.1	0.1
	KID 109XD		Kidney 2	0.1	0.2

- 22 -

	LIV 94XA		Liver 1	0	0.04
	LIV 15XA		Liver 2	48.6	0.03
	MAM A06X		Mammary 1	0	0
	MAM 59X		Mammary 2	0.9	0
5	OVR 103X		Ovary 1	0.5	2.6
	PAN 71XL		Pancreas 1	0.1	0.1
	PAN 77X		Pancreas 2	0.1	0
	PRO 20XB		Prostate 1	0.3	0.1
	PRO 12B		Prostate 2	0.3	0
10	PRO 69XB		Prostate 3	0.6	0.5
	SMI 21XA		Sm. Int. 1	0.3	0
	SMI H89		Sm. Int. 2	0.1	0.2
	STO AC44		Stomach 1	0.2	0.2
	STO AC99		Stomach 2	0.1	0.2
15	STO MT54		Stomach 3	0.3	0
	STO TA73		Stomach 4	0.4	0.7
	TST 39X		Testis	4.8	0.8
	UTR 135XO		Uterus 1	0.6	0.5
20	UTR 141XO		Uterus 2	0	0.1

0=negative

In the analysis of matching samples, the higher levels of expression were in lung, showing a high degree of tissue specificity for lung tissue. Of all the samples different than lung analyzed, only one sample (the cancer sample Liver 2 with 48.6) showed an expression comparable to the mRNA expression in lung. These results confirmed the tissue specificity results obtained with the panel of normal pooled samples (Table 2).

Furthermore, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual was compared. This comparison provides an

- 23 -

indication of specificity for the cancer stage (e.g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 3 shows overexpression of Lng109 in 16 primary lung cancer tissues compared with their respective normal adjacent (lung samples #1, 3, 4, 5, 7, 8, 9, 10, 11, 13, 14, 15, 18, 19, 20, and 21). There was overexpression in the cancer tissue for 70% of the lung matching samples tested (total of 23 lung matching samples).

10 Altogether, the high level of tissue specificity, plus the mRNA overexpression in 70% of the primary lung matching samples tested are demonstrative of Lng109 being a diagnostic marker for lung cancer.

Measurement of SEQ ID NO:4; Clone ID1355520 (1981752);
15 Gene ID236760 (Lng110)

The absolute numbers depicted in Table 4 are relative levels of expression of Lng110 in 12 normal different tissues. All the values are compared to normal testis (calibrator). These RNA samples are commercially
20 available pools, originated by pooling samples of a particular tissue from different individuals.

Table 4: Relative levels of Lng109 Expression in Pooled Samples

Tissue	NORMAL
25 Brain	0
Heart	0.003
Kidney	0.02
Liver	0
Lung	392.1
30 Mammary	0
Muscle	0
Prostate	0.1
Sm. Int.	0
Testis	1
35 Thymus	0.6
Uterus	0

- 24 -

The relative levels of expression in Table 4 show that Lng110 mRNA expression is more than 300 fold higher in the pool of normal lung (392.1) compared to all the other tissues analyzed. These results demonstrate that

5 Lng110 mRNA expression is highly specific for lung.

The absolute numbers in Table 4 were obtained analyzing pools of samples of a particular tissue from different individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue

10 samples of a single individual in Table 5.

The absolute numbers depicted in Table 5 are relative levels of expression of Lng110 in 60 pairs of matching samples. All the values are compared to normal testis (calibrator). A matching pair is formed by mRNA from the

15 cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.

Table 5: Relative levels of Lng109 Expression in Individual Samples

20	Sample ID	Cancer type	Tissue	Cancer	Matching Normal
	LNG AC82	Adenocarcinoma	Lung 1	30.8	17
	LNG 60XL	Adenocarcinoma	Lung 2	18.2	40.1
	LNG AC66	Adenocarcinoma	Lung 3	0	31.1
25	LNG AC69	Adenocarcinoma	Lung 4	44.8	5.3
	LNG AC88	Adenocarcinoma	Lung 5	239.7	78.5
	LNG AC11	Adenocarcinoma	Lung 6	10.7	1.3
	LNG AC39	Adenocarcinoma	Lung 7	134.4	0.7
	LNG AC90	Adenocarcinoma	Lung 8	373.5	4.6
30	LNG AC32	Adenocarcinoma	Lung 9	65.8	1.2
	LNG SQ9X	Squamous cell carcinoma	Lung 10	76.6	0.2
	LNG SQ45	Squamous cell carcinoma	Lung 11	21.4	105.8

- 25 -

	LNG SQ56	Squamous cell carcinoma	Lung 12	48.2	1049.1
	LNG SQ14	Squamous cell carcinoma	Lung 13	2.3	0.7
	LNG SQ32	Squamous cell carcinoma	Lung 14	3.2	0.5
	LNG SQ80	Squamous cell carcinoma	Lung 15	191.3	0.3
5	LNG SQ16	Squamous cell carcinoma	Lung 16	21.3	0.7
	LNG SQ79	Squamous cell carcinoma	Lung 17	1992	7.8
	LNG C20X	Squamous cell carcinoma	Lung 18	0.7	0.4
	LNG 47XQ	Squamous cell carcinoma	Lung 19	4.3	0
	LNG SQ44	Squamous cell carcinoma	Lung 20	0	0
10	LNG BR94	Squamous cell carcinoma	Lung 21	100.8	0
	LNG 90X	Squamous cell carcinoma	Lung 22	5.2	45.4
	LNG LC71	Large cell carcinoma	Lung 23	4.6	2.5
	LNG LC109	Large cell carcinoma	Lung 24	876.1	111.4
15	LNG 75XC	Metastatic from bone cancer	Lung 25	19	27.2
	LNG MT67	Metastatic from renal cancer	Lung 26	0	0
	LNG MT71	Metastatic from melanoma	Lung 27	0	5.2
	BLD 32XK		Bladder 1	0	0
	BLD 46XK		Bladder 2	0	0
20	CLN AS67		Colon 1	0	0
	CLN C9XR		Colon 2	0	0

- 26 -

5	CLN CM67		Colon 3	0	0
	CVX KS52		Cervix 1	1.4	0
	CVX NK23		Cervix 2	0	0
	CVX NKS18		Cervix 3	0	0
	END 28XA		Endometrium 1	0.8	0
10	ENDO 12XA		Endometrium 2	0	0
	KID 106XD		Kidney 1	0	0
	KID 107XD		Kidney 2	0	0
	KID 10XD		Kidney 3	0	0
	KID 11XD		Kidney 4	0	0
15	LIV 94XA		Liver 1	0	0
	LIV 15XA		Liver 2	0	0
	MAM A06X		Mammary 1	0	0
	MAM B011X		Mammary 2	0	0
	MAM 12X		Mammary 3	0	0
20	MAM 59X		Mammary 4	0	0
	OVR 103X		Ovary 1	0.1	0
	PAN 71XL		Pancreas 1	0	0
	PAN 77X		Pancreas 2	0	0
	PRO 20XB		Prostate 1	0	0
25	PRO 12B		Prostate 2	0	0
	SMI 21XA		Small Intestine 1	0	0
	SMI H89		Small Intestine 2	0	0
	STO AC44		Stomach 1	0	0
	STO AC99		Stomach 2	0	0
30	TST 39X		Testis	4.4	0

- 27 -

UTR 135XO		Uterus 1	0	0
UTR 141XO		Uterus 2	0	0

5 0=negative

In the analysis of matching samples, the higher levels of expression were in lung showing a high degree of tissue specificity for lung tissue. These results confirm the tissue specificity results obtained with normal pooled
10 samples (Table 4).

Furthermore, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual was compared. This comparison provides an indication of specificity for the cancer stage (e.g.
15 higher levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 5 shows overexpression of Lngl10 in 18 primary lung cancer samples compared with their respective normal adjacent (lung samples #1, 4, 5, 6, 7, 8, 9, 10, 13, 14, 15, 16, 17, 18,
20 19, 21, 23 and 24). There is overexpression in the cancer tissue for 75% of the lung matching samples tested (total of 24 primary lung matching samples).

Altogether, the high level of tissue specificity, plus the mRNA overexpression in 75% of the lung matching
25 samples tested are demonstrative of Lngl10 being a diagnostic marker for lung cancer. The amino acid sequence encoded by the open reading frame of Lngl10 is depicted in SEQ ID NO:6.

- 28 -

What is claimed is:

1. A method for diagnosing the presence of lung cancer in a patient comprising:

(a) measuring levels of LSG in cells, tissues or
5 bodily fluids in said patient; and

(b) comparing the measured levels of LSG with levels of LSG in cells, tissues or bodily fluids from a normal human control, wherein an increase in measured levels of LSG in said patient versus normal human control
10 is associated with the presence of lung cancer.

2. A method of diagnosing metastatic lung cancer in a patient comprising:

(a) identifying a patient having lung cancer that is not known to have metastasized;

15 (b) measuring LSG levels in a sample of cells, tissues, or bodily fluid from said patient for LSG; and

(c) comparing the measured LSG levels with levels of LSG in cell, tissue, or bodily fluid type of a normal human control, wherein an increase in measured LSG levels
20 in the patient versus the normal human control is associated with a cancer which has metastasized.

3. A method of staging lung cancer in a patient having lung cancer comprising:

(a) identifying a patient having lung cancer;

25 (b) measuring LSG levels in a sample of cells, tissues, or bodily fluid from said patient; and

(c) comparing measured LSG levels with levels of LSG in cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in measured LSG levels
30 in said patient versus the normal human control is associated with a cancer which is progressing and a decrease in the measured LSG levels is associated with a cancer which is regressing or in remission.

- 29 -

4. A method of monitoring lung cancer in a patient for the onset of metastasis comprising:

(a) identifying a patient having lung cancer that is
5 not known to have metastasized;

(b) periodically measuring levels of LSG in samples of cells, tissues, or bodily fluid from said patient for LSG; and

(c) comparing the periodically measured LSG levels
10 with levels of LSG in cells, tissues, or bodily fluid type of a normal human control, wherein an increase in any one of the periodically measured LSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.

15 5. A method of monitoring changes in a stage of lung cancer in a patient comprising:

(a) identifying a patient having lung cancer;

(b) periodically measuring levels of LSG in cells, tissues, or bodily fluid from said patient; and

20 (c) comparing the periodically measured LSG levels with levels of LSG in cells, tissues, or bodily fluid type of a normal human control, wherein an increase in any one of the periodically measured LSG levels in the patient versus the normal human control is associated with a
25 cancer which is progressing in stage and a decrease is associated with a cancer which is regressing in stage or in remission.

6. The method of claim 1, 2, 3, 4 or 5 wherein the LSG comprises SEQ ID NO:4 or 5.

30 7. An antibody against an LSG wherein said LSG comprises SEQ ID NO:4 or SEQ ID NO:5.

- 30 -

8. A method of imaging lung cancer in a patient comprising administering to the patient an antibody of claim 7.

9. The method of claim 8 wherein said antibody is
5 labeled with paramagnetic ions or a radioisotope.

10. A method of treating lung cancer in a patient comprising administering to the patient an antibody of claim 7.

11. The method of claim 10 wherein the antibody is
10 conjugated to a cytotoxic agent.

SEQUENCE LISTING

<110> Fei, Yang
Sun, Yongming
Recipon, Herve
Macina, Roberto A
DIADEXUS LLC

<120> A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING,
IMAGING AND TREATING LUNG CANCER

<130> DEX-0038

<140>

<141>

<150> 06/095,233

<151> 1998-08-04

<160> 6

<170> PatentIn Ver. 2.0

<210> 1

<211> 174

<212> DNA

<213> Homo sapiens

<400> 1

cataattggg cataactgtaa tattctcaga gatctatatg taaaatttgt atagtcatag 60
ttttatggtg gggtataatt gtctctagta gattctgtga gtctaaaaca ataggaagac 120
tgtgtcccat tagcttgcca tgcaattttt aactttgaca atagactttt ttg 174

<210> 2

<211> 276

<212> DNA

<213> Homo sapiens

<400> 2

aagaggagtc tggaggtagg gtccaagggc caccagccag ttggggctgc tggagggggg 60
cctggcaagg agggctctcg gggaagcacc tgtgggggtc tgcttcctga cccagggag 120
ctagaggcct ccctccctcc agggccccc aagccaggctg agccagccgc taggggcacg 180
gagcagtgcc caccttgccg ccagtgtggc cagagcttcg gccggaagga gctcagtgcg 240
ccgcaccagc gcgtgcatcg tggcccccg cctttc 276

<210> 3

<211> 347

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (279)..(280)

<220>

<221> unsure

<222> (272)

<220>

<221> unsure

<222> (311)

<400> 3

```

gttagcttca caccttcggc agcaggaggg cggcagcttc tcgcaggcgg cagggcgggc 60
ggccaggatc atgtccacca ccacatgcca agtggtggcg ttctctctgt ccatectggg 120
gctggccggc tgcatecgcg ccaccgggat ggacatgtgg agcaccagc acctgtacga 180
caaccccgct acctccgtgt tccagtacga agggctctgg aggagctgcg tgaggcagag 240
ttcaggcttc accgaatgca ggccctattt caccatccnn gnacttcag ccattgctgca 300
ggcagtgcca nccctgatga tcgtaggcat cgtctgggt gccattg 347

```

<210> 4

<211> 1016

<212> DNA

<213> Homo sapiens

<400> 4

```

acggggagag agaggagacc aggacagctg ctgagacctc taagaagtcc agatactaag 60
agcaaagatg tttaaactg ggggcctcat tgtcttctac gggctgttag ccagaccat 120
ggcccagttt ggaggcctgc ccgtgcccct ggaccagacc ctgcccctga atgtgaatcc 180
agccctgccc ttgagtccca caggctctgc aggaagcttg acaaagccc tcagcaatgg 240
cctgctgtct gggggcctgt tgggcattct ggaaaacctt ccgctcctgg acatcctgaa 300
gcctggagga ggtacttctg gtggcctcct tgggggactg cttggaaaag tgacgtcagt 360
gattcctggc ctgaacaaca tcattgacat aaaggctcact gacccccagc tgctggaact 420
tggccttgtg cagagccctg atggccaccg tctctatgtc accatccctc tcggcataaa 480
gctccaagtg aatacgcccc tggtcggtgc aagtctgttg aggctggctg tgaagctgga 540
catcactgca gaaatcttag ctgtgagaga taagcaggag aggatccacc tggctccttg 600
tgactgcacc cattcccctg gaagcctgca aatttctctg cttgatggac ttggccccct 660
ccccattcaa ggtcttctg acagcctcac agggatcttg aataaagtcc tgcctgagtt 720
ggttcagggc aacgtgtgcc ctctggtcaa tgaggttctc agaggcttgg acatcaccct 780
ggtgcatgac attgttaaca tgctgatcca cggactacag tttgtcatca aggtctaagc 840
cttcaggaa gggctggcc tctgctgagc tgcttcccag tgctcacaga tggctggccc 900
atgtgctgga agatgacaca gttgccttct ctccaggaa cctgccccct ctctttccc 960
accaggcgtg tgtaacatcc catgtgcctc acctaataaa atggtctctc ttctgc 1016

```

<210> 5

<211> 597

<212> DNA

<213> Homo sapiens

<400> 5

tggctcgtga gtcccttggg catcccgtc ctgggcaggt caccaatagg tccccgcagt 60
 tcccaatgga actgttccag tcctccccga ggctccact tcaacctgtc tgtgtctgcc 120
 caggcctgga gttgtgtgac cctccccacc gcctggcctt ctccatgggg gctggccttt 180
 tctcgggtggt gggcacctg ctgctgcccg gcctggctgc gcttgtgcag gactggcgtc 240
 ttctgcaggg gctgggtgcc ctgatgagt gactcttgct gctcttttgg gggaggaggt 300
 ggaggagacc gtgggcatcc tcaccaacgc tgcaggttcc cgccctgtt ccccgagtct 360
 ccctgctggc tgctggccac aggtcaggta gctcgagcca ggaagatcct gtggcgcttt 420
 gcagaagcca gtggcgtggg ccccggggac agttccttgg aggagaactc cctggctaca 480
 gagctgacca tgctgtctgc acggagcccc cagccccggg accactcccc actggggctt 540
 ctgcgtaccc gagtcacctg gagaaacggg cttatcttgg gcttcagctc gctgggtt 597

<210> 6

<211> 256

<212> PRT

<213> Homo sapiens

<400> 6

Met Phe Gln Thr Gly Gly Leu Ile Val Phe Tyr Gly Leu Leu Ala Gln
 1 5 10 15
 Thr Met Ala Gln Phe Gly Gly Leu Pro Val Pro Leu Asp Gln Thr Leu
 20 25 30
 Pro Leu Asn Val Asn Pro Ala Leu Pro Leu Ser Pro Thr Gly Leu Ala
 35 40 45
 Gly Ser Leu Thr Asn Ala Leu Ser Asn Gly Leu Leu Ser Gly Gly Leu
 50 55 60
 Leu Gly Ile Leu Glu Asn Leu Pro Leu Leu Asp Ile Leu Lys Pro Gly
 65 70 75 80
 Gly Gly Thr Ser Gly Gly Leu Leu Gly Gly Leu Leu Gly Lys Val Thr
 85 90 95
 Ser Val Ile Pro Gly Leu Asn Asn Ile Ile Asp Ile Lys Val Thr Asp
 100 105 110
 Pro Gln Leu Leu Glu Leu Gly Leu Val Gln Ser Pro Asp Gly His Arg
 115 120 125
 Leu Tyr Val Thr Ile Pro Leu Gly Ile Lys Leu Gln Val Asn Thr Pro
 130 135 140

Leu Val Gly Ala Ser Leu Leu Arg Leu Ala Val Lys Leu Asp Ile Thr
145 150 155 160

Ala Glu Ile Leu Ala Val Arg Asp Lys Gln Glu Arg Ile His Leu Val
165 170 175

Leu Gly Asp Cys Thr His Ser Pro Gly Ser Leu Gln Ile Ser Leu Leu
180 185 190

Asp Gly Leu Gly Pro Leu Pro Ile Gln Gly Leu Leu Asp Ser Leu Thr
195 200 205

Gly Ile Leu Asn Lys Val Leu Pro Glu Leu Val Gln Gly Asn Val Cys
210 215 220

Pro Leu Val Asn Glu Val Leu Arg Gly Leu Asp Ile Thr Leu Val His
225 230 235 240

Asp Ile Val Asn Met Leu Ile His Gly Leu Gln Phe Val Ile Lys Val
245 250 255

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/16247

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C12Q 1/58; C12P 19/34; C07H 21/04

US CL :435/6, 91.2; 536/23.5, 24.31

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 91.2; 536/23.5, 24.31

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98/20143 A1 (ABBOTT LABORATORIES) 14 May 1998, especially pages 10, 44-45 and 65.	1-5
X - Y	US 5,589,579 A (TORCZYNSKI et al) 31 December 1996, columns 10-14.	1 --- 2-5



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

21 SEPTEMBER 1999

Date of mailing of the international search report

07 OCT 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

CARLA MYERS

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/16247

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS; WEST Derwent files; DIALOG: Medline, Biosis, Embase, Scisearch, CA

search terms: lung, NSCL, cancer, tumor, carcinoma, nucleic acid, gene, mRNA, protein